My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$IBM {{ '2015-08-17T13:11:31+0000' | timeago}} • Announcement

$IBM IBM announced a significant expansion of mainframe’s strategy of embracing open source-based technologies and open-source communities to provide clients with the most secure, highest performance capabilities for an era where mainframes increasingly anchor corporate analytics and hybrid clouds.

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

User Vishnu Beri {{ '2016-10-24T17:33:28+0000' | timeago}}

Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.

User Vishnu Beri {{ '2016-10-24T17:05:39+0000' | timeago}}

Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.

User Floyd Jenks {{ '2016-10-24T15:53:54+0000' | timeago}}

$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.

$MRK {{ '2016-10-25T12:17:28+0000' | timeago}} • Webcast

$MRK said on October 24, 2016, the US Food and Drug Administration (FDA) approved KEYTRUDA as the only PD-L1 therapy for the first-line treatment of metastatic lung cancer. In 3Q16, the company reported a strong performance, reflecting growth across several priority programs, including the vaccines portfolio and also KEYTRUDA and ZEPATIER.

$PG {{ '2016-10-25T12:10:37+0000' | timeago}} • Infographic

$PG Procter & Gamble Earnings AlphaGraph: Q1 2017 Highlights

$BHI {{ '2016-10-25T12:08:53+0000' | timeago}} • Announcement

In 3Q16, $BHI experienced activity declines and project delays in the Gulf of Mexico, Norway, and West Africa deepwater operations. For 4Q16, $BHI expects activity to increase modestly in North America, and a tough pricing environment and reduced activity internationally.

$GM {{ '2016-10-25T12:06:56+0000' | timeago}} • Announcement

$GM sold 2.4MM vehicles globally in 3Q16, up 3.8% from 3Q15. Through September 30, the company sold 7.2MM vehicles globally. In the US, $GM sold 2.2MM vehicles in year-to-date and increase retail share of 0.5 points. In China, deliveries rose 9% to 2.7MM vehicles. In Europe, Opel/Vauxhall posted a 5.1% sales growth.

$GM {{ '2016-10-25T12:03:19+0000' | timeago}} • Announcement

$GM now expects full-year 2016 adjusted EPS at high end of its prior estimate of $5.50-6.00. This is based on its expected strong business results for 2H16. CFO Chuck Stevens said strong bottom line results this year puts $GM on track to deliver on annual earnings outlook and cash generation has allowed to close initial share repurchase earlier.